UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 798

Sortiert nach

HLA-DQB103:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors

Journal of investigative dermatology, 2018-05, Vol.138 (5), p.1201-1204

2018

Link zum Volltext

Verfügbarkeit prüfen

Positive association between the proinsulin-to-C-peptide ratio and prolonged hyperglycemic time in type 2 diabetes

Endocrine Journal, 2024, Vol.71(4), pp.403-408

2024

Link zum Volltext

Verfügbarkeit prüfen

Positive association between proinsulin and fatty liver index in people with type 2 diabetes

Endocrine Journal, 2024, Vol.71(2), pp.193-197

2024

Link zum Volltext

Verfügbarkeit prüfen

Thyrotoxicosis in Graves' Disease with Invasive Laryngeal Cancer

Internal Medicine, 2018/05/15, Vol.57(10), pp.1495-1496

2018

Link zum Volltext

Verfügbarkeit prüfen

Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)

Endocrine Journal, 2024, pp.EJ23-0648

2024

Link zum Volltext

Verfügbarkeit prüfen

The expression system affects the binding affinity between p75NTR and proNGF

Biochemistry and biophysics reports, 2024-07, Vol.38, p.101702-101702, Article 101702

2024

Link zum Volltext

Verfügbarkeit prüfen

IAPP toxicity activates HIF1α/PFKFB3 signaling delaying β-cell loss at the expense of β-cell function

Nature communications, 2019-06, Vol.10 (1), p.2679-17, Article 2679

2019

Link zum Volltext

Verfügbarkeit prüfen

Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy

Endocrine Journal, 2016, Vol.63(6), pp.589-596

2016

Link zum Volltext

Verfügbarkeit prüfen

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone

Journal of diabetes investigation, 2021-07, Vol.12 (7), p.1272-1277

2021

Link zum Volltext

Verfügbarkeit prüfen

Two Cases of Transiently Elevated Serum CEA Levels in Severe Hypothyroidism without Goiter

Internal Medicine, 2018/09/01, Vol.57(17), pp.2523-2526

2018

Link zum Volltext

Verfügbarkeit prüfen

Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice

Metabolism, clinical and experimental, 2019-09, Vol.98, p.27-36

2019

Link zum Volltext

Verfügbarkeit prüfen

Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment

Journal of diabetes investigation, 2021-05, Vol.12 (5), p.738-746

2021

Link zum Volltext

Verfügbarkeit prüfen

Successful management of a patient with active Cushing’s disease complicated with coronavirus disease 2019 (COVID-19) pneumonia

Endocrine Journal, 2021, Vol.68(4), pp.477-484

2021

Link zum Volltext

Verfügbarkeit prüfen

Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor

Internal Medicine, 2021/08/01, Vol.60(15), pp.2375-2383

2021

Link zum Volltext

Verfügbarkeit prüfen

Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?

Endocrine Journal, 2022, Vol.69(5), pp.495-509

2022

Link zum Volltext

Verfügbarkeit prüfen

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial

Journal of diabetes investigation, 2019-05, Vol.10 (3), p.699-705

2019

Link zum Volltext

Verfügbarkeit prüfen

Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function

Scientific reports, 2022-06, Vol.12 (1), p.9740-9740, Article 9740

2022

Link zum Volltext

Verfügbarkeit prüfen

Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring

Scientific reports, 2021-04, Vol.11 (1), p.9057-9057, Article 9057

2021

Link zum Volltext

Verfügbarkeit prüfen

Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose

Endocrine Journal, 2017, Vol.64(4), pp.417-424

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages

Scientific reports, 2018-05, Vol.8 (1), p.6864-11, Article 6864

2018

Link zum Volltext

Verfügbarkeit prüfen

Dipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study

Journal of diabetes investigation, 2021-11, Vol.12 (11), p.1978-1982

2021

Link zum Volltext

Verfügbarkeit prüfen

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes

Journal of diabetes investigation, 2021-02, Vol.12 (2), p.176-183

2021

Link zum Volltext

Verfügbarkeit prüfen

Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage

Diabetology and metabolic syndrome, 2023-10, Vol.15 (1), p.1-214, Article 214

2023

Link zum Volltext

Verfügbarkeit prüfen

A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)

PloS one, 2015-08, Vol.10 (8), p.e0135854-e0135854

2015

Link zum Volltext

Verfügbarkeit prüfen

Combination of alcohol and glucose consumption as a risk to induce reactive hypoglycemia

Journal of diabetes investigation, 2021-04, Vol.12 (4), p.651-657

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 798

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(630)
Mit Volltextzugriff
(749)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

HLA-DQB103:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors

Positive association between the proinsulin-to-C-peptide ratio and prolonged hyperglycemic time in type 2 diabetes

Positive association between proinsulin and fatty liver index in people with type 2 diabetes

Thyrotoxicosis in Graves' Disease with Invasive Laryngeal Cancer

Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)

The expression system affects the binding affinity between p75NTR and proNGF

IAPP toxicity activates HIF1α/PFKFB3 signaling delaying β-cell loss at the expense of β-cell function

Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone

Two Cases of Transiently Elevated Serum CEA Levels in Severe Hypothyroidism without Goiter

Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice

Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment

Successful management of a patient with active Cushing’s disease complicated with coronavirus disease 2019 (COVID-19) pneumonia

Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor

Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial

Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function

Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring

Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose

Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages

Dipeptidyl peptidase‐4 inhibitor might exacerbate Graves’ disease: A multicenter observational case–control study

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes

Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage

A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2)

Combination of alcohol and glucose consumption as a risk to induce reactive hypoglycemia

Suchergebnisse filtern